Taysha Gene Therapies Announces Commercial Supply Agreement With Catalent For Rett Syndrome Gene Therapy TSHA-102 Ahead Of Potential FDA Approval
Share
Why It Matters
Taysha Gene Therapies signed a deal with a company that will help make and deliver their new Rett syndrome medicine if it gets approved by the FDA. This shows the company is ready to actually sell the medicine, which is a sign of confidence in their product.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.